Michela Gallagher

Michela Gallagher

Company: AgeneBio

Job title: Founder & Chief Executive Officer

Seminars:

Live Q&A With Your Expert Speakers 10:50 am

Read more

day: Day One

Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The HOPE4MCI Trial 9:30 am

Novel therapeutic targets; hippocampal overactivity driving Alzheimer’s Disease pathology (amyloid deposition, tau progression and cortical atrophy) in patients with amnestic mild cognitive impairment Success Story: AGB101 (low dose levetiracetam) reduces hippocampal overactivity and restores task related episodic memory function in a Phase 2A study in patients with amnestic mild cognitive impairment Clinical Update: HOPE4MCI is…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.